A HER2-targeting peptide drug conjugate with better penetrability for effective breast cancer therapy
Antibody-drug conjugates (ADCs) have advantages including target specificity, wide therapeutic index and prolonged circulation half-life. A key limitation of ADCs, however, is the large size (∼150 kDa), which markedly slows ...